Heart failure & cardiomyopathies
Echocardiographic screening for heart failure and optimization of the care pathway for individuals with pacemakers: a randomized controlled trial
Primary resultResult — go to the resultHazard ratio 0.89 95% CI 0.69–1.17Authors' conclusion
The results of this trial indicate that echocardiography screening commonly identifies LVSD in individuals with pacemakers but alone does not alter outcomes.
Study context
- Population
- Patients with a pacemaker717 men
- Participants
- 1,201 patients
- Comparison
- Echocardiography screening vs usual care
- Echocardiography screeningn = 600
- Usual caren = 601reference
- Primary endpoint
- Composite of:
- Time to first HF hospitalization
- Death
Methodological detailsmulticentre
- Multicentre
Primary result
As reported in the abstract
31 months (IQR 30-40 months)
Hazard ratio
0.89
95% CI 0.69–1.17
Events by treatment group
Echocardiography screeningvs Usual care
HR 0.89 (95% CI 0.69–1.17)
Further findings
- Left ventricular systolic dysfunction (LVSD) detected (screening arm) — Echocardiography screening
- 34%
Primary outcome in LVSD, specialist clinic vs primary care (subgroup)
- Primary outcome event less frequent with specialist clinic management than with primary care
- Prespecified, nonrandomized, exploratory analysis
Original publication
Echocardiographic screening for heart failure and optimization of the care pathway for individuals with pacemakers: a randomized controlled trial. Nat Med. Published 19 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →